Teva (TEVA) Sues Forest Labs (FRX) Over Alzheimer's Disease Drug
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.05 --0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -5.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -5.6%
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) is said to have filed a lawsuit against Forest Labs (NYSE: FRX) over patent infringement, according to Bloomberg headlines.
The suit, filed in Delaware, is related to Forest's Alzheimer's disease drug Namenda XR
The patent in question is U.S. patent number 6,194,000, which was awarded to Teva in 2001.
Namenda was launched in the U.S. in June 2013.
The suit, filed in Delaware, is related to Forest's Alzheimer's disease drug Namenda XR
The patent in question is U.S. patent number 6,194,000, which was awarded to Teva in 2001.
Namenda was launched in the U.S. in June 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva in talks with Trump administration on Medicaid drug pricing
- Zillow and Redfin settle FTC antitrust case over listing partnership
- Jury finds Parse Biosciences willfully infringed 10x Genomics patents
Create E-mail Alert Related Categories
Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
